Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-112 in Glaucoma and Ocular Hypertension
NCT01279083Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jan 2011
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of evodenoson in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started Jan 2011; status: completed.
02
Drugs
evodenoson
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT01279083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01279083.